West Pharmaceutical Services (WST) Free Cash Flow (2009 - 2026)

West Pharmaceutical Services has disclosed Free Cash Flow across 18 years of filings, most recently posting $63.8 million for Q1 2026.

• Free Cash Flow for Q1 2026 came in at $63.8 million, up 9.81% year-over-year; the trailing twelve-month figure through Mar 2026 was $474.6 million (down 19.01% YoY), and the FY2025 annual result was $468.9 million, down 21.9% from the prior year.
• Free Cash Flow came in at $63.8 million for Q1 2026 at West Pharmaceutical Services, down from $175.0 million in the prior quarter.
• In the past five years, Free Cash Flow ranged from a high of $409.2 million in Q4 2024 to a low of -$50.4 million in Q3 2024.
• The 5-year median for Free Cash Flow is $107.0 million (2022), against an average of $131.7 million.
• Across the five-year window, Free Cash Flow tumbled 137.53% in 2024 and surged 365.67% in 2025, its largest moves.
• West Pharmaceutical Services' Free Cash Flow stood at $387.3 million in 2022, then sank by 66.33% to $130.4 million in 2023, then soared by 213.8% to $409.2 million in 2024, then plunged by 57.23% to $175.0 million in 2025, then tumbled by 63.54% to $63.8 million in 2026.
• The last three Free Cash Flow figures came in at $63.8 million (Q1 2026), $175.0 million (Q4 2025), and $133.9 million (Q3 2025), per Business Quant data.